/ Whitepaper: Biomarker-Guided Belatacept Conversion: A New Standard for Post-Transplant Surveillance

Whitepaper: Biomarker-Guided Belatacept Conversion: A New Standard for Post-Transplant Surveillance

Belatacept-based immunosuppression is emerging as a powerful alternative to calcineurin inhibitors (CNIs) in kidney transplant care. However, belatacept carries unique risks, including higher rates of T-cell-mediated rejection and viral complications, making precision monitoring essential for safe conversion and ongoing management.

Transplant Genomics provides advanced molecular diagnostics—TruGraf®, Eurofins TRAC™, and TRAC™ ID—that enable biomarker-guided surveillance for rejection, tissue injury, and infection risk. These tools deliver earlier, noninvasive insights compared to traditional markers like creatinine or biopsy, supporting personalized immunosuppression strategies and safer belatacept conversion protocols. By integrating these diagnostics, transplant teams can optimize outcomes, reduce unnecessary biopsies, and protect graft longevity.

What’s Inside:

  • Why Belatacept? – Advantages over calcineurin inhibitors and its growing role in kidney transplant care.
  • Key Risks & Challenges – Understanding belatacept’s risk profile, including TCMR and viral complications.
  • Precision Monitoring Tools – How TruGraf®, Eurofins TRAC™, and TRAC™ ID enable safer conversion and ongoing surveillance.
  • Clinical Insights & Case Studies – Real-world examples showing early detection and improved outcomes.
  • Future of Personalized Care – Biomarker-guided strategies for tailored immunosuppression and long-term graft protection.